Weight Research

Compounds studied in body weight reduction, adipose tissue loss, or obesity treatment. Showing 2 compounds.

← All categories
Semaglutide FDA-approved GLP-1 agonist with landmark trial data showing 15–17% body weight reduction. View research notes → Tirzepatide FDA-approved dual agonist with up to 22% body weight reduction in the SURMOUNT-1 trial. View research notes → Retatrutide Retatrutide is a synthetic peptide developed by Eli Lilly that acts as a single-molecule agonist at three distinct hormone receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. View research notes → Cagrilintide Cagrilintide is a long-acting synthetic analog of amylin, a peptide hormone that is co-secreted with insulin from pancreatic beta cells. View research notes →